256 related articles for article (PubMed ID: 16953237)
1. Predicted mechanisms of resistance to mTOR inhibitors.
Kurmasheva RT; Huang S; Houghton PJ
Br J Cancer; 2006 Oct; 95(8):955-60. PubMed ID: 16953237
[TBL] [Abstract][Full Text] [Related]
2. Updates of mTOR inhibitors.
Zhou H; Luo Y; Huang S
Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
[TBL] [Abstract][Full Text] [Related]
3. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.
Chan S
Br J Cancer; 2004 Oct; 91(8):1420-4. PubMed ID: 15365568
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to rapamycins.
Huang S; Houghton PJ
Drug Resist Updat; 2001 Dec; 4(6):378-91. PubMed ID: 12030785
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
Rao RD; Buckner JC; Sarkaria JN
Curr Cancer Drug Targets; 2004 Dec; 4(8):621-35. PubMed ID: 15578919
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Smolewski P
Anticancer Drugs; 2006 Jun; 17(5):487-94. PubMed ID: 16702804
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targets: MTOR and related pathways.
Dancey JE
Cancer Biol Ther; 2006 Sep; 5(9):1065-73. PubMed ID: 16969122
[TBL] [Abstract][Full Text] [Related]
9. Mammalian target of rapamycin: a new molecular target for breast cancer.
Mita MM; Mita A; Rowinsky EK
Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941
[TBL] [Abstract][Full Text] [Related]
10. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
11. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitors in the treatment of cancer.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2008 Nov; 17(11):1717-34. PubMed ID: 18922108
[TBL] [Abstract][Full Text] [Related]
13. NCCN Task Force Report: mTOR inhibition in solid tumors.
Figlin RA; Brown E; Armstrong AJ; Akerley W; Benson AB; Burstein HJ; Ettinger DS; Febbo PG; Fury MG; Hudes GR; Kies MS; Kwak EL; Morgan RJ; Mortimer J; Reckamp K; Venook AP; Worden F; Yen Y
J Natl Compr Canc Netw; 2008 Sep; 6 Suppl 5():S1-20; quiz S21-2. PubMed ID: 18926092
[TBL] [Abstract][Full Text] [Related]
14. Current status and challenges associated with targeting mTOR for cancer therapy.
Dowling RJ; Pollak M; Sonenberg N
BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin passes the torch: a new generation of mTOR inhibitors.
Benjamin D; Colombi M; Moroni C; Hall MN
Nat Rev Drug Discov; 2011 Oct; 10(11):868-80. PubMed ID: 22037041
[TBL] [Abstract][Full Text] [Related]
16. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Wang X; Hawk N; Yue P; Kauh J; Ramalingam SS; Fu H; Khuri FR; Sun SY
Cancer Biol Ther; 2008 Dec; 7(12):1952-8. PubMed ID: 18981735
[TBL] [Abstract][Full Text] [Related]
17. Targeting mTOR signaling for cancer therapy.
Huang S; Houghton PJ
Curr Opin Pharmacol; 2003 Aug; 3(4):371-7. PubMed ID: 12901945
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin (mTOR) Inhibitors.
Dutcher JP
Curr Oncol Rep; 2004 Mar; 6(2):111-5. PubMed ID: 14751088
[TBL] [Abstract][Full Text] [Related]
19. Rapamycins: mechanism of action and cellular resistance.
Huang S; Bjornsti MA; Houghton PJ
Cancer Biol Ther; 2003; 2(3):222-32. PubMed ID: 12878853
[TBL] [Abstract][Full Text] [Related]
20. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.
Mita M; Sankhala K; Abdel-Karim I; Mita A; Giles F
Expert Opin Investig Drugs; 2008 Dec; 17(12):1947-54. PubMed ID: 19012509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]